NEW York Stock Exchange-listed
Par Pharmaceutical Companies Inc
has announced the US$410 million
acquisition of privately held Anchen
Pharmaceuticals.
The all-cash deal will see Par take
on Anchen’s portfolio of five
commercialised products and
pipeline of 27 New Drug
applications already on file with the
Food and Drug Administration.
Par also owns Strativa
Pharmaceuticals, and has a strategy
of developing, manufacturing and
marketing “high barrier-to-entry
generic drugs and niche, innovative
proprietary pharmaceuticals”.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Aug 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Aug 11
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.